Composition and method for affecting obesity and related conditions

• US 8,809,312 B2
• Filed: 11/26/2013
• Issued: 08/19/2014
• Est. Priority Date: 04/02/2008
• Status: Expired due to Fees

• Current Assignee: Jonathan R. Brestoff, Thomas H. Reynolds IV
• Original Assignee: Thomas H. Reynolds IV
• Inventors: Brestoff, Jonathan R., Reynolds, Thomas H. IV
• Primary Examiner(s): CHONG, YONG SOO
• Application Number:
  US14/091,218
• Publication Number:
  US 20140088065A1
• Time in Patent Office: 266 Days
• Field of Search: 514/183
• US Class Current: 514/183
• CPC Class Codes: A23L 33/10 using additives addition of substantially indigestible substances A23L33/21
• CPC Class Codes: A23L 33/30 Dietetic or nutritional methods, e.g. for losing weight A23L33/10 takes precedence
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L

Abstract

A composition including an effective amount of a compound including manganese [III]tetrakis(4-benzoic acid)porphyrin (MnTBAP), derivatives or analogs thereof to induce a reduction in body weight of a mammal or to improve insulin sensitivity of an obese mammal. A method including introducing an effective amount of a compound including manganese [III]tetrakis(4-benzoic acid)porphyrin (MnTBAP), derivatives or analogs thereof to a mammal to induce a reduction in body weight or to induce an increase in metabolism or insulin sensitivity of the mammal.

Claims

1. A method of inducing an increase in metabolic rate in a mammal in need thereof comprising administering an effective amount of manganese [III] tetrakis (4-benzoic acid) porphyrin (MnTBAP) or analogs thereof.

2. The method of claim 1 wherein an effective amount of compound is an amount which further enhances insulin sensitivity.

3. The method of claim 1 wherein an effective amount of the compound is from about 2.5 mg/kg of body weight about 88 of body weight of the mammal.

4. The method of claim 1 wherein an effective amount of the compound is Introduced to the mammal on a daily basis.

5. The method of claim 1 wherein an effective amount of the compound is an amount which further treats type 2 diabetes.